Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer

Autor: Wolf, J., Seto, T., Han, J.Y., Reguart, N., Garon, E.B., Groen, H.J.M., Tan, D.S.W., Hida, T., Jonge, M. de, Orlov, S.V., Smit, E.F., Souquet, P.J., Vansteenkiste, J., Hochmair, M., Felip, E., Nishio, M., Thomas, M., Ohashi, K., Toyozawa, R., Overbeck, T.R., Marinis, F. de, Kim, T.M., Laack, E., Robeva, A., Mouhaer, S. le, Waldron-Lynch, M., Sankaran, B., Balbin, O.A., Cui, X.M., Giovannini, M., Akimov, M., Heist, R.S., GEOMETRY Mono-1

Publikováno v: New England Journal of Medicine, 383(10), 944-957. MASSACHUSETTS MEDICAL SOC

BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64a18227f05bd9fa382e68b390876ec
https://research.rug.nl/en/publications/d70eeec5-1717-4ee1-abbf-c9bf1f6ef7bb

A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer

Autor: Migliorino, M. R., Marinis, F. De, Nelli, F., Facciolo, F., Ammaturo, M. V., Cipri, A., Belli, R., Ariganello, O., Diana, F., Molfetta, M. Di

Publikováno v: Lung Cancer; 2002, Vol. 35 Issue: 3 p319-327, 9p

503PActivity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials.

Autor: Passaro, A¹ (AUTHOR), Marinis, F De² (AUTHOR), Tu, H³ (AUTHOR), Laktionov, K K⁴ (AUTHOR), Feng, J⁵ (AUTHOR), Poltoratskiy, A⁶ (AUTHOR), Zhao, J⁷ (AUTHOR), Tan, E-H⁸ (AUTHOR), Gottfried, M⁹ (AUTHOR), Lee, V¹⁰ (AUTHOR), Kowalski, D¹¹ (AUTHOR), Yang, C-T¹² (AUTHOR), Srinivasa, B¹³ (AUTHOR), Clementi, L¹⁴ (AUTHOR), Tang, W¹⁵ (AUTHOR), Huang, D C-L¹⁶ (AUTHOR), Cseh, A¹⁷ (AUTHOR), Park, K¹⁸ (AUTHOR), Zhou, C¹⁹ (AUTHOR), Wu, Y-L³ (AUTHOR)

Publikováno v: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

482PInterim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC.

Autor: Marinis, F De¹ (AUTHOR), Laktionov, K K² (AUTHOR), Poltoratskiy, A³ (AUTHOR), Egorova, I⁴ (AUTHOR), Hochmair, M⁵ (AUTHOR), Passaro, A¹ (AUTHOR), Migliorino, M R⁶ (AUTHOR), Metro, G⁷ (AUTHOR), Gottfried, M⁸ (AUTHOR), Tsoi, D⁹ (AUTHOR), Ostoros, G¹⁰ (AUTHOR), Rizzato, S¹¹ (AUTHOR), Mukhametshina, G Z¹² (AUTHOR), Schumacher, M¹³ (AUTHOR), Novello, S¹⁴ (AUTHOR), Dziadziuszko, R¹⁵ (AUTHOR), Tang, W¹⁶ (AUTHOR), Clementi, L¹⁷ (AUTHOR), Cseh, A¹⁸ (AUTHOR), Kowalski, D¹⁹ (AUTHOR)

Publikováno v: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

Cisplatin (P), etoposide (E) and gemcitabine (G), in untreated patients with small cell lung cancer (SCLC): Preliminary results of a multi-institutional phase II trial

Autor: Marinis, F. De, Cortesi, E., Paoluzzi, L., Cipri, A., Portalone, L., Nelli, F., Giampaolo, M., Ariganello, O., Diana, F., Ramponi, S.

Publikováno v: Lung Cancer; 2000, Vol. 29 Issue: 1 p67-67, 1p